At ACADIA, we are committed to improving the lives of patients with neurological and related central nervous system disorders.

About Us

ACADIA Pharmaceuticals is a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders. More »

---

News

May 20, 2013
ACADIA Pharmaceuticals Announces Exercise in Full of Option to Purchase Additional Shares and Completion of Public Offering of Common Stock

May 20, 2013
ACADIA Pharmaceuticals Added to NASDAQ Biotechnology Index

More News »

Product Candidates

We have a pipeline of product candidates led by pimavanserin, which is in Phase III development as a potential first-in-class treatment for Parkinson's disease psychosis.   More »

---

Company Information

	Learn More: Pimavanserin Phase III Program for Parkinson's Disease Psychosis »
	Investor Webcasts »
	Email Updates »